Patents Examined by Gina C Justice
  • Patent number: 11369649
    Abstract: The claimed subject matter relates to Lactobacillus paracasei-derived extracellular vesicles and a use thereof, and more particularly, to a composition for alleviating, preventing and treating an ocular disease, which includes Lactobacillus paracasei-derived extracellular vesicles as an active ingredient, capable of effectively inhibiting the occurrence of an ocular disease caused by oxidative stress-mediated cell senescence.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: June 28, 2022
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 11364189
    Abstract: The present invention relates to a method for the cosmetic treatment of keratin materials, comprising the application of a composition to the keratin materials, such as the skin, said composition comprising a compound (I), wherein R1, R2 and R3 are as defined in the description and S* is a mono or polysaccharide.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 21, 2022
    Assignee: L'OREAL
    Inventor: Marie-céline Frantz
  • Patent number: 11364215
    Abstract: The present application relates to GHB formulations and methods for manufacturing the same.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: June 21, 2022
    Assignee: JAZZ PHARMACEUTICALS IRELAND LIMITED
    Inventors: Clark Allphin, Scott Bura
  • Patent number: 11357731
    Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: June 14, 2022
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Bernard Charles Sherman, Michael Spino
  • Patent number: 11318085
    Abstract: The present disclosure relates to methods, systems and kits for treating the skin by applying onto the skin a skin tightening composition comprising 1) at least one thermoplastic elastomer and at least one adhesive polymer; and 2) a sunscreen composition comprising one or more UV filters. Methods, systems and kits comprise applying the compositions of the systems sequentially.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 3, 2022
    Assignee: L'OREAL
    Inventors: Brian Scott Bodnar, Anne-Laure Suzanne Bernard, Anil Shah, Alexandra Jane Elisa Farran
  • Patent number: 11311519
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 26, 2022
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Patent number: 11298307
    Abstract: The present invention relates to a transparent or semitransparent cosmetic composition in which the stability of amentoflavone is enhanced, and more particularly, to a transparent or semitransparent cosmetic composition, wherein a water-soluble amentoflavone-oligomer complex, in which amentoflavone is encapsulated in a hollow structure of an oligomer structure, is stabilized in a second agent containing a polyhydric alcohol, a two-liquid-type container is used to mix first and second agents before use, and hydrotrope is contained in the first agent to increase the mixing stability of the first and second agents and thereby enhance the stability of amentoflavone.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: April 12, 2022
    Assignee: Amorepacific Corporation
    Inventors: Byung Ryol Paik, Soon Ae An, Joon Young Hwang, Yong Jin Kim, Byung Fhy Suh
  • Patent number: 11291628
    Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 5, 2022
    Assignee: Cosette Pharmaceuticals, Inc.
    Inventor: Tommy L. Chau
  • Patent number: 11291618
    Abstract: A cosmetic mask composition including a combination of acrylates/VA copolymer and acrylates copolymer. The cosmetic mask composition includes about 5% to 30% by weight of acrylates/VA copolymer, and about 0.2% to 2% by weight of acrylates copolymer. The ratio of acrylates/VA copolymer to acrylates copolymer is in the range of 15:1 to 25:1.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: April 5, 2022
    Assignee: ELC Management LLC
    Inventors: Fatemeh Mohammadi, Sunni L. Tejada, Lisa Qu, Anna Czarnota, Tsung-Wei Robert Mou, Wilson A. Lee
  • Patent number: 11278520
    Abstract: A method of preventing COVID-19 infection in a healthy individual, the method comprising the steps of a) providing the healthy individual; b) administering, on day 1, 10,000 mg of vitamin C, 40,000 mg of vitamin D, and 50 mg of zinc; c) administering daily, on days 2 and 3, 10,000 mg of vitamin c and 50 mg of zinc; d) administering daily, on days 4 through 7, 3,000 mg of vitamin c and 50 mg of zinc; and e) repeating steps b) and c) for 1 to 23 weeks.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: March 22, 2022
    Inventor: Sabine Hazan
  • Patent number: 11260061
    Abstract: The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: March 1, 2022
    Assignee: ELLODI PHARMACEUTICALS, L.P.
    Inventors: Michael A. Gosselin, Jin-Wang Lai, Gopi M. Venkatesh
  • Patent number: 11260047
    Abstract: The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: March 1, 2022
    Assignee: EIDOS THERAPEUTICS, INC.
    Inventors: Jesper Jernelius, Mark Michael Menning
  • Patent number: 11260063
    Abstract: A topical composition useful for treating psoriasis and other skin disorders.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 1, 2022
    Assignee: Chem-Cure Associates LLC
    Inventor: Edward Richard Yuhas
  • Patent number: 11241404
    Abstract: The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: February 8, 2022
    Inventor: William A. Shaver
  • Patent number: 11241394
    Abstract: The present invention relates to prevention and/or treatment of diseases or disorders associated with a damaged or leaky vasculature in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating a disease or disorder associated with a damaged or leaky vasculature in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, an outer surface comprising a cellular membrane derived from a platelet; and optionally an agent for preventing, treating, diagnosing, or prognosing the disease or disorder and/or monitoring prevention or treatment of the disease or disorder. Exemplary diseases or disorders include hemorrhage (bleeding), cardiovascular diseases or disorders, diseases or disorders associated with narrowing of a blood vessel, tumors or cancers.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 8, 2022
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Che-Ming Jack Hu, Ronnie H. Fang, Brian T. Luk, Kuei-Chun Wang, Shu Chien
  • Patent number: 11229601
    Abstract: The invention relates in particular to an injectable sclerosant drug foam comprising: (i) a matrix; (ii) at least one fluid; (iii) at least one sclerosant drug; (iv) a medical gas or medical gas mixture acceptable for intravenous use, (v) wherein said matrix has physical properties, which are comparable to denatured blood, wherein the denatured blood is obtainable from a fresh human venous whole blood sample of 1 ml volume, which is heated in a cylindrical polyethylene container with 3 mm inner diameter and 3.4 mm outer diameter for about 0.5 min. to about 10 min. at a temperature of about between 70° C. and 100° C. and/or (vii) said level of denaturation is defined by the change of red-colored hemoglobin to brown as an indicator, wherein Fe2+ is reduced to Fe3+ in the hemoglobin complex to a degree of at least 80%, preferably 90% and even more preferably 95%.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 25, 2022
    Assignee: SWISS VX VENETHERAPIE UND FORSCHUNG GMBH
    Inventor: Johann Christof Ragg
  • Patent number: 11224577
    Abstract: The present invention relates to prevention and/or treatment of infection by a platelet-targeting microbe in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating (and/or related uses) infection by a platelet-targeting microbe in a subject, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, b) an outer surface comprising a cellular membrane derived from a platelet; and optionally c) an agent for preventing said infection, treating said infection, diagnosing said infection, prognosing said infection and/or monitoring prevention or treatment of said infection. Exemplary platelet-targeting infections include infections by a bacterium, a virus, a fungus and/or a parasite.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 18, 2022
    Assignee: The Regents of the University of California
    Inventors: Liangfang Zhang, Che-Ming Jack Hu, Ronnie H. Fang, Brian T. Luk, Soracha Kun Thamphiwatana
  • Patent number: 11213479
    Abstract: The present invention relates to a novel cosmetic or dermatological composition for topical or oral use, comprising at least one passionflower extract, at least edelweiss callus cells, and at least one physiologically acceptable support, to a non-therapeutic cosmetic skin treatment process using such a cosmetic composition, and also to the non-therapeutic use of such a cosmetic composition for protecting the skin against environmental attack, preventing, retarding and/or combating the signs of ageing of the skin.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: January 4, 2022
    Assignee: SOCIETE DE RECHERCHE COSMETIQUE S.A.R.L.
    Inventors: Eve Merinville, Judith Elkaim
  • Patent number: 11213535
    Abstract: The present invention is related to a composition comprising phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These components may be in isolated form or be part of an enriched plant extract. The invention is also related to the use of this composition for the treatment of renal lithiasis, preferably calcium or calcium oxalate lithiasis, either in the form of a medicament, a nutraceutical or functional food or food supplement.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: January 4, 2022
    Assignee: UNIVERSITAT DE LES ILLES BALEARS
    Inventors: Félix Grases Freixedas, Antonia Costa Bauzá, Rafael María Prieto Almirall, Adrián Rodríguez Rodríguez
  • Patent number: 11202760
    Abstract: This disclosure provides pharmaceutical compositions comprising midodrine, a pharmaceutically acceptable salt thereof, desglymidodrine, a pharmaceutically acceptable salt thereof, or a combination therefore that can be administered to a human subject in need thereof in a supine position. The disclosure also provides pharmaceutical compositions which can be administered once-a-day. This disclosure further provides pharmaceutical compositions comprising an extended release composition and providing a delayed release period between about 30 min to about 12 hours.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 21, 2021
    Assignee: XENAMED CORP.
    Inventors: Yogesh Dandiker, Maulik Panchal, Xiao Yu